GEN Exclusives

More »

GEN News Highlights

More »
Nov 6, 2006

Ablynx Licenses Nanobodies to Wyeth for Clinically Validated Target

  • Ablynx and Wyeth Pharmaceuticals will team up to discover, develop, and commercialize Nanobodies® directed at the tumor necrosis factor alpha protein and its receptors that target diseases in multiple therapeutic areas, under an exclusive research collaboration and license agreement with.

    Ablynx has granted Wyeth exclusive, worldwide rights to Nanobodies targeting the clinically validated target tumor necrosis factor alpha. The companies will together advance these biologics through preclinical development.

    Potential payments to Ablynx could total up to $212.5 million for the successful development and commercialization of multiple products. This includes initial payment, research support, and milestone payments. In addition Ablynx will receive royalties on product sales.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »